

REMARKS

The application is to be amended as previously set forth. All amendments are made without prejudice or disclaimer. No new matter has been added.

The Communication mailed February 17, 2006 has been received and reviewed. Claims 1-31 are pending in the application and subject to restriction. Applicants elect, without traverse, to prosecute the claims of Group XI, *i.e.*, claims 28-31. Upon election of Group XI, applicants were further required to elect a specific sequence identified by its corresponding SEQ ID NO. Applicants elect signature sequence OtS1-B7. The nucleotide sequence of signature sequence OtS1-B7 is disclosed as part of SEQ ID NO: 129 (Contig 1A gene). The nucleotide sequence of signature sequence OtS1-B7 can be deduced based on the specification, in particular paragraph [00138], and SEQ ID NO: 129.

[00138] 6. The OtS1-B7 gene comprises the OtS1-B7 fragment:
nt 8426-8463 identical to nt 1-38 of OtS1-B7 (3'-part of exon 7)
nt 8955-9106 identical to nt 39-190 of OtS1-B7 (exon 8)
nt 10386-10495 identical to nt 191-300 of OtS1-B7 (exon 9)
nt 11618-11732 identical to nt 301-415 of OtS1-B7 (5'-part of exon 10)
(Specification, paragraph [00138]).

Applicants were further required to elect a single species from each of the species groups A through H designated in the Communication. Applicants elect species as follows:

- A. Applicants elect a DC-SIGN molecule involved in modulating an immune response.
Claims 28-31 read on the elected species. Claims 28-31 are generic with respect to the elected species.
- B. Applicants elect cytokines. Claims 28-31 read on the elected species. Claims 28-31 are generic with respect to the elected species.
- C. Applicants elect a TH2 mediated immune response. Claims 28-31 read on the elected species. Claims 28-31 are generic with respect to the elected species.
- D. Applicants elect airway hyperresponsiveness. Claims 28-31 read on the elected species. Claims 28-31 are generic with respect to the elected species.
- E. Applicants elect an antibody. Claims 28-31 read on the elected species. Claims 28-30 are generic with respect to the elected species.
- F. Applicants elect an antibody. Claims 28-31 read on the elected species. Claims 28-30

are generic with respect to the elected species.

G. Applicants elect the product of the gene identified by SEQ ID NO: 129 or an equivalent of SEQ ID NO: 129 in mammal. Claims 28-31 read on the elected species. Claims 28-31 are generic with respect to the elected species.

H. Applicants elect airway hyperreactivity. Claims 28-31 read on the elected species. Claims 28-31 are generic with respect to the elected species.

If questions should remain after consideration of the foregoing, the Examiner is kindly requested to contact applicants' agent at the address or telephone number given herein.

Respectfully submitted,



Li Feng, Ph.D.
Registration No. 57,292
Agent for Applicants
TRASKBRITT, PC
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: April 12, 2006

Enclosures: Petition for Extension of Time
Check No. 9409 in the amount of \$120

Document in ProLaw